ScreenerHero

TLXTelix Pharmaceuticals Limited American Depositary Shares

NAS · US · Healthcare · Biotechnology · telixpharma.com
11.33USDMkt Cap: 3.84B $P/E: 113.30

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segment…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.84B $
Enterprise Value4.43B $
Revenue (TTM)803.79M $
Gross Profit426.44M $
Net Income (TTM)-7.13M $
Revenue/Share2.379 USD
Last Price11.33 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees1.1K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)113.30
P/E (Forward)86.40
PEG—
EV/EBITDA136.51
EV/Revenue5.51
P/S5.23
P/B10.13
EPS (TTM)-0.02
EPS (Forward)0.14
52W Range
11.1970% of range11.39
52W High11.39 USD
52W Low11.19 USD
Profitability
Gross Margin53.05%
Oper. Margin1.94%
EBITDA Margin4.04%
Profit Margin-0.89%
ROE-1.72%
ROA-0.61%
Growth
Revenue Growth49.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.29M $
CapEx (TTM)43.78M $
FCF Margin-4.56%
FCF Yield-0.96%
Net Debt325.24M $
Net Debt/EBITDA10.02
Balance Sheet
Debt/Equity1.12
Current Ratio1.43
Quick Ratio1.21
Book Value/Sh1.226 USD
Cash/Share0.4190 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)21.07 USD
Upside (mean)+86.0%
Target Range19.89 USD – 22.01 USD
$19.89+86.0% to mean$22.01
# Analysts4
Ownership
Shares Out.338.78M
Float272.81M
Insiders0.00%
Institutions0.98%
Short Interest
Short Ratio2.0d
Short % Float0.09%
Short % Out.0.08%
Shares Short277.66K
Short (prev mo.)162.63K
Technical
SMA 5010.81 (+4.8%)
SMA 2009.348 (+21.2%)
Beta0.60
S&P 52W Chg21.00%
Avg Vol (30d)299.20K
Avg Vol (10d)91.60K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—